
Ablynx has achieved a pre-clinical proof-of-concept with a nanobody construct as part of its immuno-oncology collaboration with Merck – triggering …
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns

